NASDAQ:XERS - Xeris Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Xeris Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.86 -0.18 (-2.98 %) (As of 01/24/2020 03:01 PM ET) Add Compare Today's Range$5.71Now: $5.86▼$6.0550-Day Range$5.55MA: $7.20▼$9.1752-Week Range$5.30Now: $5.86▼$15.82Volume2,450 shsAverage Volume290,677 shsMarket Capitalization$158.22 millionP/E RatioN/ADividend YieldN/ABeta-0.48 ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XERS Previous Symbol CUSIPN/A CIKN/A Webhttp://www.xerispharma.com/ Phone844-445-5704Debt Debt-to-Equity Ratio1.33 Current Ratio5.96 Quick Ratio5.96Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.46 million Price / Sales64.32 Cash FlowN/A Price / Cash FlowN/A Book Value$3.61 per share Price / Book1.62Profitability EPS (Most Recent Fiscal Year)($4.99) Net Income$-60,080,000.00 Net Margins-6,697.33% Return on Equity-150.08% Return on Assets-83.18%Miscellaneous Employees90 Outstanding Shares27,000,000Market Cap$158.22 million Next Earnings Date3/4/2020 (Estimated) OptionableNot Optionable Receive XERS News and Ratings via Email Sign-up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:XERS Rates by TradingView Xeris Pharmaceuticals (NASDAQ:XERS) Frequently Asked Questions What is Xeris Pharmaceuticals' stock symbol? Xeris Pharmaceuticals trades on the NASDAQ under the ticker symbol "XERS." How were Xeris Pharmaceuticals' earnings last quarter? Xeris Pharmaceuticals Inc (NASDAQ:XERS) released its earnings results on Thursday, November, 7th. The company reported ($1.22) earnings per share for the quarter, beating the consensus estimate of ($1.23) by $0.01. The firm had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.20 million. Xeris Pharmaceuticals had a negative return on equity of 150.08% and a negative net margin of 6,697.33%. View Xeris Pharmaceuticals' Earnings History. When is Xeris Pharmaceuticals' next earnings date? Xeris Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Xeris Pharmaceuticals. What price target have analysts set for XERS? 2 equities research analysts have issued 1 year price targets for Xeris Pharmaceuticals' stock. Their forecasts range from $18.00 to $22.00. On average, they expect Xeris Pharmaceuticals' share price to reach $20.00 in the next year. This suggests a possible upside of 241.3% from the stock's current price. View Analyst Price Targets for Xeris Pharmaceuticals. What is the consensus analysts' recommendation for Xeris Pharmaceuticals? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xeris Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xeris Pharmaceuticals. What are Wall Street analysts saying about Xeris Pharmaceuticals stock? Here are some recent quotes from research analysts about Xeris Pharmaceuticals stock: 1. According to Zacks Investment Research, "Xeris Pharmaceuticals, Inc. produces peptides, proteins, antibodies, molecules, auto-injectors, multi-dose pens and infusion pumps to treat endocrine and metabolic diseases. The company's proprietary formulation technologies consist of XeriSol (TM) and XeriJect(TM). Xeris Pharmaceuticals, Inc. is based in Chicago, United States. " (11/16/2019) 2. Mizuho analysts commented, "We applied a weighted average valuation methodology (DCF+EV/Sales) to derive our $27 PT. Our assumptions include: Launch of the glucagon rescue pen in the U.S. market in 4Q19, with unadjusted peak-sales of $454 mil in 2028 (current PoS: 90%)." (9/10/2019) Has Xeris Pharmaceuticals been receiving favorable news coverage? News coverage about XERS stock has been trending somewhat negative recently, according to InfoTrie. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Xeris Pharmaceuticals earned a news impact score of -1.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Xeris Pharmaceuticals. Are investors shorting Xeris Pharmaceuticals? Xeris Pharmaceuticals saw a decrease in short interest in December. As of December 31st, there was short interest totalling 2,100,000 shares, a decrease of 7.1% from the December 15th total of 2,260,000 shares. Based on an average daily trading volume, of 193,700 shares, the short-interest ratio is presently 10.8 days. Currently, 9.4% of the company's stock are short sold. View Xeris Pharmaceuticals' Current Options Chain. Who are some of Xeris Pharmaceuticals' key competitors? Some companies that are related to Xeris Pharmaceuticals include Axovant Sciences (AXON), Cara Therapeutics (CARA), Vectura Group (VEGPF), Urogen Pharma (URGN), AC Immune (ACIU), Morphic (MORF), Kadmon (KDMN), MacroGenics (MGNX), Kura Oncology (KURA), Neoleukin Therapeutics (NLTX), Crinetics Pharmaceuticals (CRNX), Magenta Therapeutics (MGTA), Milestone Pharmaceuticals (MIST), Prothena (PRTA) and BioDelivery Sciences International (BDSI). What other stocks do shareholders of Xeris Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xeris Pharmaceuticals investors own include AbbVie (ABBV), Amicus Therapeutics (FOLD), Zynerba Pharmaceuticals (ZYNE), AT&T (T), ACADIA Pharmaceuticals (ACAD), ADMA Biologics (ADMA), Amarin (AMRN), Axsome Therapeutics (AXSM), Five Prime Therapeutics (FPRX) and GlycoMimetics (GLYC). Who are Xeris Pharmaceuticals' key executives? Xeris Pharmaceuticals' management team includes the folowing people: Mr. Paul R. Edick, Pres, CEO & Chairman (Age 63)Mr. Barry M. Deutsch, Chief Financial Officer (Age 54)Mr. John P. Shannon, Exec. VP & COO (Age 57)Dr. Steven J. Prestrelski, Co-Founder & Chief Scientific Officer (Age 55)Ms. Allison Wey, Sr. VP of Investor Relations & Corp. Communications When did Xeris Pharmaceuticals IPO? (XERS) raised $75 million in an IPO on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager. How do I buy shares of Xeris Pharmaceuticals? Shares of XERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Xeris Pharmaceuticals' stock price today? One share of XERS stock can currently be purchased for approximately $5.86. How big of a company is Xeris Pharmaceuticals? Xeris Pharmaceuticals has a market capitalization of $158.22 million and generates $2.46 million in revenue each year. The company earns $-60,080,000.00 in net income (profit) each year or ($4.99) on an earnings per share basis. Xeris Pharmaceuticals employs 90 workers across the globe.View Additional Information About Xeris Pharmaceuticals. What is Xeris Pharmaceuticals' official website? The official website for Xeris Pharmaceuticals is http://www.xerispharma.com/. How can I contact Xeris Pharmaceuticals? Xeris Pharmaceuticals' mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The company can be reached via phone at 844-445-5704 or via email at [email protected] MarketBeat Community Rating for Xeris Pharmaceuticals (NASDAQ XERS)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 84 (Vote Outperform)Underperform Votes: 91 (Vote Underperform)Total Votes: 175MarketBeat's community ratings are surveys of what our community members think about Xeris Pharmaceuticals and other stocks. Vote "Outperform" if you believe XERS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XERS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/24/2020 by MarketBeat.com StaffFeatured Article: Dividend Aristocrat Index
